Evaluating the impact of Apomorphine injections and pumps on movement and quality of life in Iraqi patients with Parkinson’s disease.

A Prospective Evaluation of Motor and Non-Motor Symptom Changes Following Subcutaneous Apomorphine Therapy in Advanced Parkinson’s Disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202605760621936

Enrollment

Registered

2026-05-26

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases

Interventions

apomorphine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: parkinson disease more than 3 years, average off 3 hours per day , motor fluctuations not adequately controlled on oral treatment

Exclusion criteria

Exclusion criteria: symptomatic clinically relevant uncontrolled orthostatic hypotension , prolonged QT duration , clinically relevant cognitive decline , moderate psychosis ,

Design outcomes

Primary

Measure	Time frame
Decrease in off hours and reduce use of oral medication	—

Secondary

Measure	Time frame
Reduction in oral medication, improvement in Non-Motor Symptoms, on time without troublesome dyskinesia	—

Countries

Iraq

Contacts

Public ContactHuda Mashhadani

college of medicine university of baghdad

huda.s@comed.uobaghdad.edu.iq96477587071

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026